Should All Breast Cancer Patients with Symptomatic Bone Metastases be Treated with Bisphosphonates? The Case in Support
- 30 April 2004
- journal article
- Published by Elsevier in Clinical Oncology
- Vol. 16 (2), 108-111
- https://doi.org/10.1016/j.clon.2004.01.004
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesionCancer, 2003
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancerBMJ, 2003
- Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronateSupportive Care in Cancer, 2003
- Bisphosphonates for the relief of pain secondary to bone metastasesCochrane Database of Systematic Reviews, 2002
- Bisphosphonates for breast cancerPublished by Wiley ,2002
- Bisphosphonates for cancer patients: why, how, and when?Supportive Care in Cancer, 2001
- Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treatment Reviews, 2001
- Zoledronic acid versus pamidronate as palliative therapy in cancer patients: A Canadian time and motion analysisJournal of Oncology Pharmacy Practice, 2001
- Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compoundJournal of Bone and Mineral Research, 1994